Exploring Sensus Healthcare, Inc. (SRTS) Investor Profile: Who’s Buying and Why?

You're looking at Sensus Healthcare, Inc. (SRTS) and the numbers from the first nine months of 2025 are defintely a mixed bag. The company posted a net loss of $4.6 million year-to-date, with Q3 revenue at just $6.9 million, a clear signal of pressure on their core Superficial Radiotherapy (SRT) system sales, yet the stock still trades around $4.04 a share as of mid-November. So, why are major institutional players like Vanguard Group Inc. and Pacific Ridge Capital Partners still holding a combined total of over 1.3 million shares as of the Q3 2025 filings? The answer lies in the regulatory shift: the Centers for Medicare & Medicaid Services (CMS) just established first-ever dedicated CPT® codes for SRT, a move that provides crucial reimbursement certainty and could fundamentally change the unit economics for their Fair Deal Agreements (FDAs). Is this simply a value trap, or are these institutional investors banking on the $24.5 million in cash and the new CMS codes to drive a massive inflection point in 2026?

Who Invests in Sensus Healthcare, Inc. (SRTS) and Why?

You're looking at Sensus Healthcare, Inc. (SRTS), a medical device company with a small-cap valuation and a lot of volatility. The investor base here is a classic mix of long-term institutions and nimble retail traders, but what's really driving the action is a bet on regulatory clarity and a successful shift to a recurring revenue model.

The core takeaway is that institutional money is taking a measured, long-term view on the company's Superficial Radiation Therapy (SRT) technology, while retail investors are often reacting to near-term earnings swings and insider buying. It's a growth play, defintely not a dividend stock.

Key Investor Types: A Breakdown of SRTS Ownership

Sensus Healthcare, Inc.'s ownership profile, as of late 2025, shows a significant split, which is common for a small-cap stock with a market capitalization around $64.47 million. Institutional investors hold a meaningful but not dominant share, leaving a large portion of the stock in the hands of individual and retail investors.

Institutional ownership sits at roughly 27.96% of shares outstanding, according to recent data. These are the big players like Vanguard Group Inc. and Dimensional Fund Advisors LP, who often hold the stock as part of broader index or small-cap value funds. Insider ownership, which is the management team and board, is relatively high at about 16.61%, signaling strong conviction from those who run the business. The remaining portion is largely held by retail investors.

The hedge fund activity, a subset of institutional ownership, is dynamic. In the third quarter of 2025, for instance, we saw 13 institutional investors add shares while 34 decreased their positions, showing significant disagreement on the near-term outlook. That's a lot of churn in a short period.

• Institutional Investors: ~27.96% ownership.
• Insider Investors: ~16.61% ownership.
• Retail/Public Investors: The majority of the remaining float.

Investment Motivations: Betting on Regulatory and Growth Catalysts

Investors are attracted to Sensus Healthcare, Inc. (SRTS) for three main reasons: its unique market position, the potential for a growth rebound, and recent regulatory tailwinds.

The company's flagship SRT-100 Vision system offers a non-invasive, cost-effective alternative to more complex procedures like Mohs surgery for non-melanoma skin cancer and keloids. This niche market position is a strong selling point for value investors. Plus, the stock has been trading at low multiples, leading some analysts to call it undervalued despite a Q2 2025 net loss of $1.0 million. You're buying the turnaround story here, not the current earnings.

The biggest recent catalyst is the regulatory clarity provided by the Centers for Medicare & Medicaid Services (CMS). In Q3 2025, CMS established new, dedicated CPT codes (Current Procedural Terminology) for SRT, which is a huge deal. This validation is expected to strengthen adoption and provide reimbursement certainty for physician partners, which should drive sales growth in 2026 and beyond. Management is also actively developing new products, like the Transdermal Infusion Product (TBI), to expand its offerings, which excites growth-focused funds. For a deeper dive into the company's core business model, you can check out Sensus Healthcare, Inc. (SRTS): History, Ownership, Mission, How It Works & Makes Money.

Investment Strategies: Value, Growth, and Event-Driven Trading

The strategies used by Sensus Healthcare, Inc. investors reflect the company's small size and its position as a medical device firm undergoing a transition. You see a clear divergence in approach:

Value and Long-Term Holding: Large passive funds like Vanguard and Dimensional Fund Advisors hold shares for the long haul, likely driven by the company's strong balance sheet-it exited Q2 2025 with $22.2 million in cash and no debt. They see the underlying value in the technology and are willing to ride out the short-term bumps, like the net loss of $4.6 million for the first nine months of 2025.

Growth and Event-Driven Trading: This strategy is more common among hedge funds and active retail traders. They are focused on the expected sales increase from the Fair Deal Agreements (FDA) in the second half of 2025 and the impact of the new CMS codes. The stock's high beta of 1.27 means its price volatility is higher than the market average, making it attractive for short-term trading. We also see this strategy in the recent insider buying, where the CEO purchased shares in November 2025, which often attracts event-driven investors looking for a signal of confidence.

Here's the quick math on the analyst view: the average 12-month price target is $8.00, which represents a forecasted upside of over 100% from the stock's price of around $3.95 in late 2025. That kind of upside is a clear signal for growth investors. What this estimate hides, still, is the execution risk on the new sales model and the timing of the full impact from the CMS codes.

Institutional Ownership and Major Shareholders of Sensus Healthcare, Inc. (SRTS)

You're looking at Sensus Healthcare, Inc. (SRTS), a smaller-cap stock, and trying to figure out who the big money is betting on-or against. The short answer is that institutional ownership sits at a significant 27.96% of shares outstanding, but the third quarter of 2025 saw a clear net outflow of capital from the stock. This is a critical signal, but it's not the whole story.

For a company with a market capitalization of roughly $64.47 million, the actions of large funds-the institutional investors-can dramatically influence the share price. Right now, the total value of institutional holdings is around $18 million, spread across approximately 4,197,479 shares. This level of institutional involvement means you need to pay close attention to their buying and selling patterns, which often dictate near-term volatility.

Top Institutional Investors: Who Holds the Keys?

The institutional investor landscape for Sensus Healthcare, Inc. (SRTS) is dominated by passive index funds and specialist small-cap managers. These are the holders with the largest stakes, as reported in their most recent filings for the 2025 fiscal year, specifically Q3 data. The largest single holder is Vanguard Group Inc., a behemoth in the index fund world, which held 728,916 shares.

The top institutional shareholders, who collectively own a meaningful chunk of the company, include:

• Vanguard Group Inc.: 728,916 shares
• Dimensional Fund Advisors LP: 569,311 shares
• Pacific Ridge Capital Partners LLC: 573,389 shares
• Divisadero Street Capital Management LP: 452,897 shares

It's important to remember that firms like Vanguard and Dimensional Fund Advisors often hold shares through various index and quantitative strategies, so their positions are less about a conviction call on Sensus Healthcare, Inc. (SRTS) specifically and more about tracking a benchmark. Their selling can be automatic, not strategic. That's a key distinction for a small-cap like this.

Changes in Ownership: The Q3 2025 Exodus

The most telling data point is the recent trend in ownership changes. In Q3 2025, the number of institutions decreasing their stake significantly outweighed those increasing it. We saw 34 institutional investors decrease their positions, while only 13 added shares. Honestly, that's a red flag for momentum, suggesting a net loss of institutional confidence.

Here's the quick math on the largest recent selling, which shows the magnitude of the change:

The total removal of 668,880 shares by Kingstone Capital Partners Texas, LLC, a complete exit, is a massive move for a small-cap. But still, some funds are buying, seeing value where others see risk. For example, DIVISADERO STREET CAPITAL MANAGEMENT, LP added 128,224 shares, a 39.5% increase, and PACIFIC RIDGE CAPITAL PARTNERS, LLC added 118,628 shares, boosting their position by 26.1%. This split tells you the market is defintely divided on the company's near-term outlook.

Impact of Institutional Investors: The Price and Strategy Lever

Institutional investors play a dual role in Sensus Healthcare, Inc. (SRTS). First, their net selling creates downward pressure on the stock price, which is a simple supply-and-demand dynamic. When large blocks of shares hit the market, the price tends to fall, which is what you've seen with the stock's 52-week price change showing a decline of -48.83%.

Second, these large investors can influence the company's strategy and governance, especially if they are activist funds. While the recent selling suggests dissatisfaction with performance or outlook-perhaps related to concerns over reimbursement cuts for skin substitute treatments-there is a counter-signal you can't ignore: insider buying. The CEO, Joseph C. Sardano, and other executives have been acquiring shares, with the CEO purchasing 25,000 shares for an estimated $100,750. That's a strong vote of confidence from the people who know the business best, which often offsets some of the negative sentiment from institutional selling.

The institutional selling is a risk, but the insider buying is a clear opportunity signal. You need to weigh the technical pressure from the funds against the fundamental confidence from the management team. For a deeper dive into the company's fundamentals that might be driving these conflicting decisions, you should check out Breaking Down Sensus Healthcare, Inc. (SRTS) Financial Health: Key Insights for Investors.

Key Investors and Their Impact on Sensus Healthcare, Inc. (SRTS)

You want to know who is buying Sensus Healthcare, Inc. (SRTS) and why, because understanding the big money's moves is half the battle in small-cap investing. The direct takeaway is this: institutional investors are currently mixed, showing a clear split between those trimming positions and others building new or adding to existing stakes, but the company's own insiders are signaling strong confidence with recent open-market purchases.

As of late 2025, institutional owners hold about 29.25% of the company's stock, while individual insiders own a substantial 16.98%, which is a high percentage that aligns management's interests very closely with shareholders. This is defintely a stock where management's skin is in the game.

Notable Institutional Players and Their Q3 2025 Shifts

The institutional landscape for Sensus Healthcare, Inc. (SRTS) is a study in divergence. We see major index funds like Vanguard Group Inc. and Dimensional Fund Advisors LP among the largest holders, which is typical for any public company. But the interesting action comes from the active managers and hedge funds, which are making sharp, contrasting moves based on their near-term outlooks.

For example, in the third quarter of 2025, we saw significant accumulation from a few key players. Divisadero Street Capital Management, LP, a new holder, added 128,224 shares, increasing their position by over 39.5%. Pacific Ridge Capital Partners, LLC also showed conviction, adding 118,628 shares, a 26.1% increase. These buyers are betting on the company's core Superficial Radiation Therapy (SRT) technology and its global expansion strategy.

However, the same period saw major exits. KINGSTONE CAPITAL PARTNERS TEXAS, LLC completely removed their entire stake of 668,880 shares, and PERRITT CAPITAL MANAGEMENT INC cut their position by nearly 78.9%, removing 469,692 shares. This selling pressure likely reflects concerns over reimbursement cuts for certain treatments or the company's recent Q3 2025 net loss of $0.06 per share, despite beating analyst revenue forecasts of $6.25 million with a reported $6.9 million in sales. It's a risk/reward split right now.

Insider Buying and Strategic Board Influence

The most compelling signal comes from the C-suite and the boardroom. Recent insider buying is a strong, concrete vote of confidence. CEO Joseph C. Sardano purchased 25,000 shares on November 18, 2025, for a total value of $100,750. Also, Director Eric Sachetta, who was just appointed to the Board in November 2025, bought 2,500 shares on November 13, 2025, for $11,250. This is the leadership team putting their own capital on the line.

Here's the quick math: when the CEO buys a six-figure block of stock on the open market, it tells you they see a disconnect between the current price and the company's intrinsic value, especially when the Q3 2025 cash position is a solid $24.5 million. Their action directly counteracts the institutional selling pressure, suggesting the insiders believe the market is over-discounting the stock's future potential.

The appointment of Eric Sachetta to the Board of Directors is also a key move, reflecting the strategic influence of investors. Sachetta, who is the Chief Wealth Services Officer at Sachetta, LLC, brings an advisory and financial planning focus to the board, which is crucial for a small-cap company looking to maximize shareholder returns and navigate the current challenging market. You can learn more about the company's direction here: Mission Statement, Vision, & Core Values of Sensus Healthcare, Inc. (SRTS).

• CEO Joseph C. Sardano bought 25,000 shares in November 2025.
• Director Eric Sachetta bought 2,500 shares in November 2025.
• Insider buying signals strong confidence in the face of a $22.5 million year-to-date revenue figure for the first nine months of 2025.

Mapping Near-Term Risks and Opportunities for Action

The primary risk is the volatility created by the institutional churn, which can keep the stock price depressed in the near term. The opportunity, however, is the clear signal from management and the accumulation by growth-focused funds like Divisadero Street Capital Management, LP and Pacific Ridge Capital Partners, LLC. They are looking past the Q3 2025 revenue decline, which was driven by lower unit sales, and focusing on the long-term adoption of the SRT-100 Vision™ system.

For you, the investor, the action is simple: look for a clear catalyst that shifts the institutional sentiment from mixed to positive. That catalyst could be a major new distribution deal or a significant beat on the Q4 2025 earnings, which would confirm the insiders' confidence. Until then, the stock trades on a tug-of-war between short-term selling and long-term insider conviction.

Market Impact and Investor Sentiment

You want to know who is buying Sensus Healthcare, Inc. (SRTS) and why, and the answer is a classic split: Insiders are buying aggressively, but institutional money is net selling, which is why the stock price is struggling. The overall investor sentiment is currently mixed, leaning cautious, but the conviction from company leadership is a powerful counter-signal you can't ignore.

In the third quarter of 2025 (Q3 2025), professional money managers showed a net decrease in their positions. We saw 34 institutional investors decrease their holdings in Sensus Healthcare, Inc., while only 13 added shares. This institutional caution is a major headwind for the stock.

• Largest Institutional Removal: KINGSTONE CAPITAL PARTNERS TEXAS, LLC removed 668,880 shares in Q3 2025, valued at an estimated $2,100,283.
• Largest Institutional Addition: DIVISADERO STREET CAPITAL MANAGEMENT, LP added 128,224 shares, a 39.5% increase, valued at an estimated $402,623.

The institutional picture is complex, but the insider activity is crystal clear: they are buying. CEO Joseph C Sardano purchased 25,000 shares for an estimated $100,750 in the last six months, and President Michael Sardano made three purchases totaling 3,000 shares for an estimated $11,430. This is a strong vote of confidence from the people who know the business best.

Recent Market Reactions to Ownership Shifts

The stock market has reacted sharply to bad news and has been slow to reward the good. The most significant move this year came after the Q2 2025 earnings report in August, where the stock dropped a massive 25.79% in premarket trading, signaling deep investor concern over the company's financial health.

Despite this, the company reported Q3 2025 revenue of $6.88 million, which modestly beat the analyst consensus of $6.31 million. The Earnings Per Share (EPS) of ($0.06) also beat the consensus loss of ($0.12). Still, the stock price as of November 20, 2025, was near its 52-week low of $3.03, trading at $3.990. This tells me the market is focusing more on the ongoing profitability challenges-the company had a negative net margin of 2.26% and a negative return on equity of 1.58%-than on the modest revenue beat.

The recent insider purchases, like Director Eric Sachetta's buy of 2,500 shares on November 13, 2025, for $11,250, have not been enough to reverse the broader trend, but they do put a floor under the stock. You can review the strategic direction driving this insider confidence in the Mission Statement, Vision, & Core Values of Sensus Healthcare, Inc. (SRTS).

Analyst Perspectives and Key Investor Impact

Wall Street's professional analysts are telling you to wait and see, but they see massive upside if the company executes. The consensus rating from five Wall Street analysts is a 'Hold,' which is the analyst's way of saying, 'Don't sell your shares, but don't rush to buy more either.'

The key takeaway is the consensus price target: the average twelve-month forecast is $8.00, with a high target of $10.00 and a low of $6.00. This implies a forecasted upside of over 102% from the stock's recent price of $3.95.

Here's the quick math on the price targets versus the current stock price:

The analyst price cuts from firms like HC Wainwright & Co. (from $12.00 to $8.00) and Lake Street (from $13.00 to $6.00) following the Q2 miss show that key investors are directly impacting analyst models. What this estimate hides is the risk of dilution, which analysts warn may negatively impact shareholder value. The analysts are betting on the long-term growth story of Superficial Radiation Therapy (SRT) technology, but they've adjusted their near-term expectations for execution and profitability.